Part of the recent literature on the evaluation of surrogate endpoints is started by a definition of validity in terms of both trial-level and individual-level association between a potential surrogate and a true endpoint. In another part, we review the main considerable statistical methods being proposed for the evaluation of a biomarker as surrogate endpoints, which have developed and consider how the validation process might be arranged within the regulatory and practical constraints evaluation. In the present work, we propose a new. Bayesian approach to evaluate individual level surrogacy. Deferent variations to prior distributions were implemented for responses with binomial distribution. Then these methods are compared in a simulation study. Finally, we apply and compare the previous and new methodology using a clinical study.